Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study;Efficacité et tolérance du trastuzumab en association avec oxaliplatine et fluoropyrimidine ; pour des patients avec adénocarcinome métastatique de l'estomac ou de la jonction œso-gastrique : une étude rétrospective

Bulletin du Cancer

Volumn 102, Issue 4, 2015, Pages 324-331

  Soularue, Émilie ^a   Cohen, Romain ^a   Tournigand, Christophe ^b   Zaanan, Aziz ^c   Louvet, Christophe ^d   Bachet, Jean Baptiste ^e   Hentic, Olivia ^f   Samalin, Emmanuelle ^g   Chibaudel, Benoist ^h,i   de Gramont, Aimery ^h   André, Thierry ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f BEAUJON HOSPITAL   (France)

^g CENTRE VAL D AURELLE   (France)

^h Hopital Franco britannique   (France)

ⁱ Research Innovation   (France)

Author keywords

Oxaliplatin; Stomach neoplasms; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; OXALIPLATIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFUSION RELATED REACTION; MALE; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; LOWER ESOPHAGUS SPHINCTER; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; STOMACH NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84930913376     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2014.08.001     Document Type: Article

References (42)

1. [1] Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C., Negri, E., European cancer mortality predictions for the year 2013. Ann Oncol 24 (2013), 792–800.
2. [2] Siegel, J.R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J Clin 63 (2013), 11–30.
3. [3] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
4. [4] Kamangar, F., Dores, G.M., Anderson, W.F., Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006), 2137–2150.
5. [5] Ferro, A., Peleteiro, B., Malvezzi, M., Bosetti, C., Bertuccio, P., Levi, F., et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50 (2014), 1330–1344.
6. [6] Wagner, A.D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., Fleig, W.E., Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (2006), 2903–2909.
7. [7] Lutz, M.P., Wilke, H., Wagener, D.J.T., Vanhoefer, U., Jeziorski, K., Hegewisch-Becker, S., et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 25 (2007), 2580–2585.
8. [8] Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 (2008), 215–221.
9. [9] Lordick, F., Lorenzen, S., Yamada, Y., Ilson, D., Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer 17 (2014), 213–225.
10. [10] Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006), 4991–4997.
11. [11] Al-Batran, S.-E., Hartmann, J.T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 (2008), 1435–1442.
12. [12] Ajani, J.A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28 (2010), 1547–1553.
13. [13] Kang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non-inferiority trial. Ann Oncol 20 (2009), 666–673.
14. [14] Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 (2008), 36–46.
15. [15] Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
16. [16] Louvet, C., André, T., Tigaud, J.M., Gamelin, E., Douillard, J.Y., Brunet, R., et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20 (2002), 4543–4548.
17. [17] Okines, A.F.C., Norman, A.R., McCloud, P., Kang, Y.-K., Cunningham, D., Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20 (2009), 1529–1534.
18. [18] Hudis, C.A., Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 357 (2007), 39–51.
19. [19] Gravalos, C., Jimeno, A., HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19 (2008), 1523–1529.
20. [20] Hofmann, M., Stoss, O., Shi, D., Büttner, R., van de Vijver, M., Kim, W., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52 (2008), 797–805.
21. [21] Janjigian, Y.Y., Werner, D., Pauligk, C., Steinmetz, K., Kelsen, D.P., Jäger, E., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23 (2012), 2656–2662.
22. [22] Chua, T.C., Merrett, N.D., Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer 130 (2012), 2845–2856.
23. [23] Sheng, W.Q., Huang, D., Ying, J.M., Lu, N., Wu, H.M., Liu, Y.H., et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 24 (2013), 2360–2364.
24. [24] Bang, Y.J., Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 46 (2012), 637–648.
25. [25] Shiroiwa, T., Fukuda, T., Shimozuma, K., Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer 105 (2011), 1273–1278.
26. [26] Gomez-Martin, C., Plaza, J.C., Pazo-Cid, R., Salud, A., Pons, F., Fonseca, P., et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 31 (2013), 4445–4452.
27. [27] Palacio, S., Loaiza-Bonilla, A., Kittaneh, M., Kyriakopoulos, C., Ochoa, R.E., Escobar, M., et al. Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res 34 (2014), 301–306.
28. [28] Hegewisch-Becker, S., Moorahrend, E., Kröning, H., Petersen, V., Hannig, C., Pott, D., et al. Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): findings from the German non-interventional observational study HerMES. J Clin Oncol, 30, 2012 [abstract 4065].
29. [29] Gong, J., Liu, T., Fan, Q., Bai, L., Bi, F., Qin, S., et al. A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: update results of efficacy and toxicity. J Clin Oncol, 32, 2014 [abstract 102].
30. [30] Ryu, M.-H., Ryoo, B.-Y., Park, Y.S., Park, S.R., Kim, J.G., Han, H.-S., et al. Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol, 32, 2014 [abstract 83].
31. [31] Ding, X., Fan, Y., Che, X., Qu, J., Xu, L., Liu, J., et al. Trastuzumab and oxaliplatin exhibit a synergistic antitumour effect in HER2-postive gastric cancer cells. Anticancer Drugs 25 (2014), 315–322.
32. [32] Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457 (2010), 299–307.
33. [33] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
34. [34] Caussanel, J.P., Lévi, F., Brienza, S., Misset, J.L., Itzhaki, M., Adam, R., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer 82 (1990), 1046–1050.
35. [35] Zheng, H., Takahashi, H., Murai, Y., Cui, Z., Nomoto, K., Miwa, S., et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 60 (2007), 273–277.
36. [36] Bang, Y., Chung, H., Xu, J., Lordick, F., Sawaki, A., Lipatov, O., et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol, 27, 2009 [abstract 4556].
37. [37] Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29 (2011), 1715–1721.
38. [38] Rougier, P., Ducreux, M., Mahjoubi, M., Pignon, J.P., Bellefqih, S., Oliveira, J., et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30 (1994), 1263–1269.
39. [39] Mitry, E., Taïeb, J., Artru, P., Boige, V., Vaillant, J.-N., Clavero-Fabri, M.-C., et al. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol 15 (2004), 765–769.
40. [40] Louvet, C., Carrat, F., Mal, F., Mabro, M., Beerblock, K., Vaillant, J.-C., et al. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest 21 (2003), 14–20.
41. [41] Henson, D.E., Dittus, C., Younes, M., Nguyen, H., Albores-Saavedra, J., Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol 128 (2004), 765–770.
42. [42] Tanner, M., Hollmén, M., Junttila, T.T., Kapanen, A.I., Tommola, S., Soini, Y., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16 (2005), 273–278.